Education
About Us
Working with TipRanks
Follow Us
Genmab A/S (DE:GE9)
XETRA:GE9
GE9 Stock Chart & Stats
€246.10
€3.40(1.61%)
At close: 4:00 PM EST
€246.10
€3.40(1.61%)
Day’s Range― - ―
52-Week Range€155.80 - €299.90
Previous CloseN/A
Volume0.00
Average Volume (3M)115.00
Market Cap
€16.11B
Enterprise Value€63.39B
Total Cash (Recent Filing)€3.23B
Total Debt (Recent Filing)€143.00M
Price to Earnings (P/E)11.5
Beta0.49
Next Earnings
May 07, 2026EPS Estimate
1.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.38
Shares Outstanding64,238,410
10 Day Avg. Volume196
30 Day Avg. Volume115
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€313.21Price Target Upside27.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
FY26 Catalysts And CommercializationThree material FY26 catalysts, combined with sustained investment in commercial infrastructure, provide visibility into EBIT growth and help offset reliance on Darzalex royalty income.
Head-and-neck Asset PotentialThe wholly owned head‑and‑neck candidate could deliver substantial upside if pivotal outcomes mirror metastatic benefits, enabling label expansion and a larger addressable market.
Late-stage Clinical CatalystsLate-stage clinical readouts across multiple programs could materially increase confidence in future revenue growth if results confirm encouraging early‑phase signals.
Bears Say
Clinical Setback: Missed Overall SurvivalMissing the overall survival endpoint in a second‑line monotherapy trial represents a clinical setback that could complicate regulatory discussions and market perception.
Emerging Competition In Frontline DLBCLGrowing competition in frontline DLBCL and adjacent markets may constrain peak uptake and put pressure on pricing and market share for the company's therapies.
Regulatory Risk From Confirmatory TrialsA failed confirmatory trial could jeopardize later‑line approval for a key program, creating regulatory uncertainty and reducing the asset's commercial value.
Genmab A/S News
GE9 FAQ
What was Genmab A/S’s price range in the past 12 months?
Genmab A/S lowest stock price was €155.80 and its highest was €299.90 in the past 12 months.
What is Genmab A/S’s market cap?
Genmab A/S’s market cap is €16.11B.
When is Genmab A/S’s upcoming earnings report date?
Genmab A/S’s upcoming earnings report date is May 07, 2026 which is in 77 days.
How were Genmab A/S’s earnings last quarter?
Genmab A/S released its earnings results on Feb 17, 2026. The company reported €0.382 earnings per share for the quarter, missing the consensus estimate of €2.627 by -€2.245.
Is Genmab A/S overvalued?
According to Wall Street analysts Genmab A/S’s price is currently Undervalued.
Does Genmab A/S pay dividends?
Genmab A/S does not currently pay dividends.
What is Genmab A/S’s EPS estimate?
Genmab A/S’s EPS estimate is 1.67.
How many shares outstanding does Genmab A/S have?
Genmab A/S has 64,238,410 shares outstanding.
What happened to Genmab A/S’s price movement after its last earnings report?
Genmab A/S reported an EPS of €0.382 in its last earnings report, missing expectations of €2.627. Following the earnings report the stock price went up 3.58%.
Which hedge fund is a major shareholder of Genmab A/S?
Currently, no hedge funds are holding shares in DE:GE9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
GE9 Stock 12 Month Forecast
Average Price Target
€313.21
▲(27.27% Upside)
Technical Analysis
Options Prices
Currently, No data available
---